Comparison of Demand for Drugs for COVID-19 Treatment, Other Drugs Early in Pandemic in Italy

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, FEBRUARY 8, 2021

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2020.37060?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=020821

About JAMA Network Open: JAMA Network Open is the new online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

 

What The Study Did: The National Health Service in Italy provides universal coverage to citizens but because no approved drug was available for COVID-19, patients received potentially effective drugs, participated in clinical trials, accessed compassionate drug use programs or self-medicated. This study evaluated changes in drug demand during the early phase of the COVID-19 outbreak in Italy compared with the period before the outbreak.

Authors: Adriana Ammassari, M.D., of the Italian Medicines Agency in Rome, is the corresponding author.

 

(doi:10.1001/jamanetworkopen.2020.37060)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.